|
Renal Cell Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We amplified and sequenced the multiple arginine coding area of the ARP gene in primary head and neck, non-small cell lung, and renal cell cancers.
|
9230196 |
1997 |
|
Renal Cell Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine-rich protein and is mutated in renal cell carcinomas.
|
8649854 |
1996 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
We have reported the presence of a specific mutation (ATG50-->AGG) or deletion of codon 50 of the ARP gene in different tumor types (Shridhar et al., 1996, 1996a).
|
9174057 |
1997 |
|
Syphilis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
From September 2009 to August 2013, we collected 658 clinical specimens from 375 patients who presented with syphilis for genotyping to examine the number of 60-bp repeats in the acidic repeat protein (arp) gene, T. pallidum repeat (tpr) polymorphism, and tp0548 gene, and to detect A2058G and A2059G point mutations by restriction fragment length polymorphism.
|
24438059 |
2014 |
|
Pancreatic carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ARP gene are thus commonly observed in pancreatic cancer, as well as many other cancers.
|
9174057 |
1997 |
|
Pancreatic carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
To investigate simultaneously UGT1A7, UGT1A9, ARP, SPINK and CFTR genes to verify whether genetic polymorphisms predispose to the development of pancreatic cancer (PC).
|
17072959 |
2006 |
|
Malignant neoplasm of pancreas
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
To investigate simultaneously UGT1A7, UGT1A9, ARP, SPINK and CFTR genes to verify whether genetic polymorphisms predispose to the development of pancreatic cancer (PC).
|
17072959 |
2006 |
|
Malignant neoplasm of pancreas
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ARP gene are thus commonly observed in pancreatic cancer, as well as many other cancers.
|
9174057 |
1997 |
|
Tumor Cell Invasion
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Total IgG levels to 11 different proteins known or predicted to be involved in reticulocyte binding or invasion (ARP, GAMA, P41, P12, PVX_081550, and five members of the PvRBP family), as well as the leading pre-erythrocytic vaccine candidate (CSP) were measured using a multiplexed bead-based assay.
|
28454546 |
2017 |
|
Esophageal Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
To examine the involvement of the ARP gene in esophageal cancer, we screened mutations around codon 50 in 35 ESC tumours and matched normal tissues.
|
10767373 |
2000 |
|
Esophageal carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To examine the involvement of the ARP gene in esophageal cancer, we screened mutations around codon 50 in 35 ESC tumours and matched normal tissues.
|
10767373 |
2000 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, they were also found in its corresponding normal tissues, suggesting that variation of the ARP gene found in ESC is polymorphic.
|
10767373 |
2000 |
|
Malignant neoplasm of esophagus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To examine the involvement of the ARP gene in esophageal cancer, we screened mutations around codon 50 in 35 ESC tumours and matched normal tissues.
|
10767373 |
2000 |
|
Reperfusion Injury
|
0.200 |
Biomarker
|
disease |
RGD |
Induction profile of MANF/ARMET by cerebral ischemia and its implication for neuron protection.
|
19773801 |
2010 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF) promote the survival of midbrain dopaminergic neurons which degenerate in Parkinson's disease (PD).
|
27425895 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, little is known about endogenous concentrations of MANF and CDNF in human PD patients, and their relation to PD pathogenesis.
|
31555085 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects neurons and repairs the Parkinson disease-like symptoms in a rat 6-hydroxydopamine model.
|
21047780 |
2011 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown positive results in protecting and repairing dopaminergic neurons in various models of PD.
|
26616211 |
2016 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) was originally identified as a secreted trophic factor for dopamine neurons <i>in vitro.</i> It protects and restores damaged cells in rodent models of Parkinson's disease, brain and heart ischemia, spinocerebellar ataxia and retina <i>in vivo</i>.
|
30386256 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intrastriatal injection of mesencephalic astrocyte-derived neurotrophic factor (MANF) protein has been shown to provide neuroprotective and neurorestorative effects in a 6-hydroxydopamine (6-OHDA) - lesioned rat model of Parkinson's disease.
|
28131727 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The selective, neuroprotective effect of MANF for dopaminergic neurons suggests that it may be indicated for the treatment of Parkinson's disease.
|
12794311 |
2003 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study suggests MANF exhibits potential as a neuroprotective agent for PD therapy.
|
29959908 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glial cell line-derived neurotrophic factor (GDNF), cerebral dopamine neurotrophic factor (CDNF), and mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown neuroprotective and restorative effects on nigral dopaminergic neurons in various animal models of Parkinson's disease.
|
29349573 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the above premise, we focus on the protective effects of NTFs, especially CDNF and MANF, on nigrostriatal DAergic neurons in PD.
|
29305570 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many groups, including ours, have proved that MANF rescues neuronal loss in several neurological disorders, such as Parkinson's disease and cerebral ischemia.
|
30760285 |
2019 |